top of page
![alkemistBio2.png](https://static.wixstatic.com/media/8b61c2_4e0a06ddf35c4d089b58c0d32bdfff95~mv2.png/v1/fill/w_289,h_124,al_c,q_85,usm_0.66_1.00_0.01,enc_auto/alkemistBio2.png)
![IMG_7714_edited_edited.jpg](https://static.wixstatic.com/media/8b61c2_81f629ec54d8458082e6279a0ce29ece~mv2.jpg/v1/fill/w_89,h_59,al_c,q_80,usm_0.66_1.00_0.01,blur_2,enc_auto/8b61c2_81f629ec54d8458082e6279a0ce29ece~mv2.jpg)
ALKemist Bio
Next generation cell therapies for ALK-positive cancer patients
Our Vision
We aim to offer a cell therapy approach to target ALK-positive cancer cells, responsible for the acquisition of resistance and low progression-free survival of ALK-positive patients.
![Prova1_edited.jpg](https://static.wixstatic.com/media/8b61c2_6f3739878e2a4dc8875092ece56a38ee~mv2.jpg/v1/fill/w_147,h_58,al_c,q_80,usm_0.66_1.00_0.01,blur_2,enc_auto/8b61c2_6f3739878e2a4dc8875092ece56a38ee~mv2.jpg)
ALK positive tumors
ALK-positive (ALK+) cancer is mainly present in patients in the form of non-small cell lung cancer, but it can also originate in many other parts of the body, including the brain and breast.
​
ALK oncogene
Anaplastic lymphoma kinase (ALK) was originally discovered in 1994, in anaplastic large-cell lymphoma cells. An oncogene is a gene that is a mutated and is the main driver of cancer cells.
​
bottom of page